Cellectis Presents Preclinical Data for Two Gene Therapies
Cellectis presented preclinical data for two novel gene therapies targeting RAG1 severe combined immunodeficiency and Hyper IgE syndrome. The results were shared at the ESGCT congress.
Cellectis, a gene-editing company, presented initial preclinical data for two novel gene therapies targeting RAG1 severe combined immunodeficiency (SCID) and Hyper IgE syndrome at the European Society of Gene and Cell Therapy (ESGCT) Congress in October 2021. The presentations focused on potential treatments for rare genetic immune disorders.
The research, conducted in collaboration with the University Medical Center Freiburg and its Center for Chronic Immunodeficiency, utilized Cellectis' TALEN® gene-editing technology. This platform aims to correct genetic defects at the cellular level, offering potential new avenues for patients with these conditions. RAG1 deficiency is a life-threatening condition requiring immediate intervention, while Hyper IgE syndrome leads to recurrent infections and significant health complications.
The preclinical findings demonstrated the technology's capability in developing therapeutic strategies for individuals lacking effective treatment options. Cellectis is advancing its research and development efforts to move these promising therapies towards clinical trials. The company's focus on gene therapy for genetic diseases underscores its commitment to addressing unmet medical needs.
The ESGCT Congress serves as a key platform for advancements in gene and cell therapy. Cellectis' presentation highlighted the company's ongoing contributions to the field and its dedication to progressing treatments for rare genetic conditions.